Lessons from the bare lymphocyte syndrome: Molecular mechanisms regulating MHC class II expression

Immunological Reviews

Volumn 178, Issue , 2000, Pages 148-165

  Waldburger, J M ^a   Masternak, K ^a   Muhlethaler Mottet, A ^a   Villard, J ^a   Peretti, M ^a   Landmann, S ^a   Reith, W ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; REGULATOR PROTEIN; TRANSACTIVATOR PROTEIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; BARE LYMPHOCYTE SYNDROME; CANCER IMMUNOTHERAPY; GENE THERAPY; GENETIC COMPLEMENTATION; GENETIC HETEROGENEITY; HETEROZYGOTE DETECTION; HUMAN; NONHUMAN; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW;

EID: 0034511922     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2000.17813.x     Document Type: Review

References (174)

1. Genomic structure and function in the MHC
2. MHC and T cell development
3. Assembly, transport, and function of MHC class II molecules
4. Major histocompatibility complex class II deficiency: Clinical manifestations, immunologic features, and outcome
5. Combined immunodeficiency with defective expression in MHC class II genes
6. Regulation of MHC class II genes: Lessons from a disease
7. Major histocompatibility complex class II deficiency: A clinical review
8. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases
9. Regulation of major histocompatibility complex class II genes: X, Y and other letters of the alphabet
10. Sequences and factors: A guide to MHC class-II transcription
11. Regulation of MHC gene expression
12. Regulation of transcription of MHC class II genes
13. The DMB promoter: Delineation, in vivo footprint, trans-activation, and trans-dominant suppression
14. HLA-DMA and HLA-DMB gene expression functions through the conserved S-X-Y region
15. Sequences homologous to class II MHC W, X, and Y elements mediate constitutive and IFN-γ-induced expression of human class II-associated invariant chain gene
16. Human major histocompatibility complex class II-associated invariant chain gene promoter. Functional analysis and in vivo protein/DNA interactions of constitutive and IFN-γ-induced expression
17. Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription
18. Developing and shedding inhibitions: How MHC class II molecules reach maturity
19. Invariant chain structure and MHC class II function
20. Induction of MHC class I expression by the MHC class II transactivator CIITA
21. Site α is crucial for two routes of IFN γ-induced MHC class I transactivation: The ISRE-mediated route and a novel pathway involving CIITA
22. The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and β2-microglobulin genes
23. Shared regulatory elements in the promoters of MHC class I and class II genes
24. Complementation cloning of mammalian transcriptional regulators: The example of MHC class II gene regulators
25. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency
26. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X
27. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency
28. A novel DNA binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome)
29. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients
30. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency
31. Primary immunodeficiency diseases: Report of a WHO scientific group
32. The bare lymphocyte syndrome
33. Failure of lymphocyte-membrane HLA A and B expression in two siblings with combined immunodeficiency
34. Impaired cell-to-cell interaction in partial combined immunodeficiency with variable expression of HLA antigens
35. Clinical and immunological studies in a patient with the "bare lymphocyte" syndrome
36. Defective expression of HLA-D-region determinants in children with congenital agammaglobulinemia and malabsorption: A new syndrome
37. Combined immunodeficiency with defective expression of HLA: Modulation of an abnormal HLA synthesis and functional studies
38. Combined immunodeficiency disease associated with absence of cell surface HLA A and B antigen
39. Two complementation groups account for most cases of inherited MHC class II deficiency
40. Molecular basis of major histocompatibility class II deficiency
41. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes
42. Analysis of transcripts of genes located within the HLA-D region in B-cells from an HLA-severe combined immunodeficiency individual
43. Normal T cell receptor V β usage in a primary immunodeficiency associated with HLA class II deficiency
44. Human T cell repertoire generation in the absence of MHC class II expression results in a circulating CD4+CD8-population with altered physicochemical properties of complementarity-determining region 3
45. T cell development in a major histocompatibility complex class II-deficient patient
46. A trans-acting class II regulatory gene unlinked to the MHC controls expression of HLA class II genes
47. Protease treatment of nuclear extracts distinguishes between class II MHC XI box DNA-binding proteins in wild-type and class II-deficient B cells
48. CLass II MHC transcriptional mutants are defective in higher order complex formation
49. Congenital immunodeficiencies associated with absence of HLA class II antigens on lymphocytes result from distinct mutations in trans-acting factors
50. Class II-antigen-negative patient and mutant B-cell lines represent at least three, and probably four, distinct genetic defects defined by complementation analysis
51. Genetic complexity of regulatory mutants defective for HLA class-II gene-expression
52. Human B cell variants immunoselected against a single Ia antigen subset have lost expression in several Ia antigen subsets
53. Stable variants affecting B cell alloantigens in human lymphoid cells
54. Analysis of the defect in IFN-γ induction of MHC class II genes in G1B cells: Identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor
55. The DNA-binding defect observed in major histocompatibility complex class II regulatory mutants concerns only one member of a family of complexes binding to the X boxes of class II promoters
56. Regulatory factor X, a bare lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex
57. Functional complementation of MHC class II regulatory mutants by the purified X box binding protein RFX
58. Analysis of mutations and chromosomal localisation of the gene encoding RFX5, a novel transcription factor affected in major histocompatibility complex class II deficiency
59. Molecular genetics of the bare lymphocyte syndrome
60. Molecular analysis of an MHC class II deficiency patient reveals a novel mutation in the RFX5 gene
61. Discoordinate expression of invariant chain and MHC class II genes in class II transactivator-transfected fibroblasts defective for RFX5
62. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency
63. Genetic and molecular definition of complementation group D in MHC class II deficiency
64. Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B
65. The bare lymphocyte syndrome: Molecular clues to the transcriptional regulation of major histocompatibility complex class II genes
66. aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression
67. Human chromosome 16 encodes a factor involved in induction of class II major histocompatibility antigens by interferon γ
68. Class II transactivator regulates the expression of multiple genes involved in antigen presentation
69. Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A
70. Defective MHC class II expression m an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene
71. Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA
72. Characterization of the expressed CIITA allele in the class II MHC transcriptional mutant RJ2.2.5
73. A functionally essential domain of RFX5 mediates activation of MHC class II promoters by promoting cooperative binding between RFX and NF-Y
74. Dissection of functional NF-4-RFX cooperative interactions on the MHC class II Ea promoter
75. Orientation and positional mapping of the subunits of the multicomponent transcription factors RFX and X2BP to the major histocompatibility complex class II transcriptional enhancer
76. RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom
77. The dimerization/repression domain of RFX1 is related to a conserved region of its yeast homologues Crtl and Sakl: A new function for an ancient motif
78. The fungal CPCR1 protein, which binds specifically to β-lactam biosynthesis genes, is related to human regulatory factor X transcription factors
79. Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding
80. Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex
81. Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis
82. In vivo footprinting of MHC class II genes: Bare promoters in the bare lymphocyte syndrome
83. Three in vivo promoter phenotypes in MHC class II deficient combined immunodeficiency
84. Inherited immunodeficiency with a defect in a major histocompatibility complex class II promoter-binding protein differs in the chromatin structure of the HLA-DRA gene
85. The molecular biology of the CCAAT-binding factor NF-Y
86. Purified X2 binding protein (X2BP) cooperatively binds the class II MHC X box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome
87. CREB regulates MHC class II expression in a CIITA-dependent manner
88. Cooperative binding between factors RFX and X2bp to the X and X2 boxes of MHC class II promoters
89. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes
90. CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors
91. Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF -Y
92. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex
93. Stereospecific alignment of the X and Y elements is required for major histocompatibility complex class II DRA promoter function
94. Structural constraints within a trimeric transcriptional regulatory region: Constitutive and interferon-γ inducible expression of the HLA-DRA gene
95. Structural and functional diversity in the leucine-rich repeat family of proteins
96. Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy
97. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element
98. Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants
99. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: Generation of transdominant-negative mutants
100. Activation of class II MHC genes requires both the X box and the class II transactivator (CIITA)
101. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency
102. Interactions between tobacco mosaic virus and the tobacco N gene
103. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-κB
104. Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain
105. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant
106. The class II trans-activator CIITA interacts with the TBP-associated factor TAF II 32
107. Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein
108. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection
109. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator
110. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes
111. CIITA stimulation of transcription factor binding to major histocompatibility complex class II and associated promoters in vivo
112. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes
113. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation
114. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5
115. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome
116. GTP binding by class II transactivator: Role in nuclear import
117. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA
118. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: Acquisition of antigen processing and presentation capacity
119. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA
120. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes
121. Class II transactivator and class II MHC gene expression in microglia: Modulation by the cytokines TGF-β, IL-4, IL-13 and IL-10
122. IFN-γ regulation of the type IV class II transactivator promoter in astrocytes
123. Activation of the MHC class II transactivator CIITA by interferon-γ requires cooperative interaction between Stat1 and USF-1
124. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA
125. Two distinct y interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor β
126. Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-γ, STAT1, and TGF-β-regulated expression of the class II transactivator gene
127. Stat1 α expression is involved in IFN-γ induction of the class II transactivator and class II MHC genes
128. CIITA activates the expression of MHC class II genes in mouse T cells
129. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells
130. MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression
131. IL-1 β inhibits IFN-γ-induced class II MHC expression by suppressing transcription of the class II transactivator gene
132. TGF-β suppresses IFN-γ induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression
133. TGF-β attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action
134. Human cytornegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway
135. + T-cell response is mediated by repression of gamma interferon-induced class II transactivator expression
136. Modulation of major histocompatibility class II protein expression by varicella-zoster virus
137. Attenuation of MHC class II expression in macrophages infected with Mycobacterium boris bacillus Calmette-Guérin involves class II transactivator and depends on the Nramp1 gene
138. Chlamydia inhibits interferon γ-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1
139. Quantitative control of MHC class II expression by the transactivator CIITA
140. Interferon (IFN) β acts downstream of IFN-γ-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-γ
141. Differential selectivity of CIITA promoter activation by IFN-γ and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-α
142. TNF-α suppresses IFN-γ-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNA
143. An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator
144. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression
145. Mice lacking the transcription factor CIITA-a second look
146. Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis
147. A novel element and a TEF-2-1ike element activate the major histocompatibility complex class II transactivator in B-lymphocytes
148. Isolation of a B-cell-specific promoter for the human class II transactivator
149. The jak-STAT pathway
150. Jaks and STATs: Biological implications
151. The role of interferon regulatory factors in the interferon system and cell growth control
152. Down-regulation of interferon-γ signaling by gene transfer of Stat1 mutant in mesangial cells
153. The chicken β2-microglobulin gene is located on a non-major histocompatibility complex microchromosome: A small, G+C-rich gene with X and Y boxes in the promoter
154. Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIITA
155. Synergistic induction of HLA class I expression by RelA and CIITA
156. Signaling and transcription in T helper development
157. A novel role for the major histocompatibility complex class II transactivator CIITA in the repression of IL-4 production
158. Activation of HIV-1 transcription by the MHC class II transactivator
159. Reduced IL-4-, lipopolysaccharide-, and IFN-γ-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain
160. Residual MHC class II expression on mature dendritic cells and activated B cells in RFX5-deficient mice
161. The thymus in "bare lymphocyte" syndrome: Significance of expression of major histocompatibility complex antigens on thymic epithelial cells in intrathymic T-cell maturation
162. The thymus in "bare lymphocyte" syndrome
163. + T cells in major histocompatibility complex class II-deficient mice
164. Prenatal diagnosis of severe combined immunodeficiency with defective synthesis of HLA molecules
165. Bone marrow transplantation in major histocompatibility complex class II deficiency: A single-center study of 19 patients
166. Successful related umbilical cord blood transplantation for graft failure following T cell-depleted non-identical bone marrow transplantation in a child with major histocompatibility complex class II deficiency
167. Major histocompatibility complex class II deficiency needs an early diagnosis: Report of a case
168. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection
169. On the role of thymic epithelium vs. bone marrow-derived cells in repertoire selection of T cells
170. Rejection of mouse sarcoma cells after transfection of MHC class II genes
171. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection
172. Interferon gamma (IFNγ) gene transfer of an EMT6 tumor that is poorly responsive to IFNγ stimulation: Increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC
173. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules
174. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth